Please login to the form below

Not currently logged in
Email:
Password:

linagliptin

This page shows the latest linagliptin news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer already has an existing relationship with Yuhan, which acts as the South Korean marketer for three of the German firm’s Eli Lilly-partnered diabetes therapies, Tradjenta (linagliptin), Trajenta Duo ... linagliptin/metformin) and Jardiance

Latest news

More from news
Approximately 3 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Notable points are that despite the considerable promotion and, some would say, superior clinical data, none of the SGLT2s has exceeded Trajenta (linagliptin) - a 4th entrant DPP4 in sales.

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    This includes Germany-based Boehringer Ingelheim's disapproval of the generic comparator used in IQWiG's AMNOG assessment of the diabetes medicine Trajenta (linagliptin).

  • A new dogma in HTA assessment A new dogma in HTA assessment

    The G-BA had specified that linagliptin should be compared with a drug from the sulphonylurea class, such as glibenclamide or glimepiride. ... However, IQWiG was unable to infer any such benefit from the dossier because the manufacturers compared

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Out of the 10 products assessed last year, four have obtained poor innovation scores: Esbriet (pirfenidone), Livazo (pitavastatin), Yellox (bromfenac) and Trajenta (linagliptin) and a majority of manufacturers have struggled – sometimes

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...